Bladder cancer
INACTIVE --- It’s getting personalised: first-line therapy of synchronous or metachronous mUCa

Christine (54 years old)

Christine is a 54-year-old librarian passionate about fantasy novels. She is a huge fan of the Game of Thrones series and every time she gets cold chills, she says: “Winter is coming.”

She was diagnosed with metastatic UCa of the bladder during investigation of dysuria. Somatic tumour testing did not show FGFR2 or FGFR3 alterations.

Assessment summary:

  • No relevant past medical history
  • CT scan of chest, abdomen and pelvis: diffuse liver and lung metastases
  • ECOG PS: 1
  • GFR: 90 ml/min
  • PD-L1 expression: high

She received 4 cycles of gemcitabine + cisplatin with partial response. She has now developed significant neuropathy and fatigue and does not want more of this chemotherapy.

Which treatment option would you choose for this patient?